Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial (HALT-C)
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or for Patients With Noncirrhotic Fibrosis at Baseline, an Increase in the Ishak Hepatic Fibrosis Score of 2 or More Points
1400 days (3.85 years) post randomization
No
Gregory T. Everson, M.D.
Principal Investigator
UCHSC (University of Colorado)
United States: Food and Drug Administration
HALT C
NCT00006164
June 2000
October 2009
Name | Location |
---|---|
University of Michigan | Ann Arbor, Michigan 48109-0624 |
University of Connecticut Health Center | Farmington, Connecticut 06360-7106 |
Massachusetts General Hospital | Boston, Massachusetts 02114-2617 |
University of California-Irvine/VA Medical Center-Long Beach | Long Beach, California 90822 |
USC School of Medicine | Los Angeles, California 90033 |
UCHSC (University of Colorado) | Denver, Colorado 80262 |
Lds, Niddk, Nih | Bethesda, Maryland 20892-1800 |
UMass Memorial HealthCare, University Campus | Worcester, Massachusetts 01655 |
Saint Louis University | St. Louis, Missouri 63104 |
University of Texas Southwestern - Dallas | Dallas, Texas 75390-9195 |
Medical College of Virginia | Richmond, Virginia 23298-0341 |